Ampio Pharmaceuticals (AMPE) Price & Analysis

Q: What is Ampio Pharmaceuticals, Inc.’s market cap?

Ampio Pharmaceuticals, Inc.’s market cap is $2.38K.

Q: How were Ampio Pharmaceuticals, Inc.’s earnings last quarter?

Ampio Pharmaceuticals, Inc. released its earnings results on May 11, 2023. The company reported -$0.264 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.264.

Q: Is Ampio Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts Ampio Pharmaceuticals, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Ampio Pharmaceuticals, Inc. pay dividends?

Ampio Pharmaceuticals, Inc. pays a Notavailable dividend of $209.7 which represents an annual dividend yield of N/A. See more information on Ampio Pharmaceuticals, Inc. dividends here

Q: How many shares outstanding does Ampio Pharmaceuticals, Inc. have?

Ampio Pharmaceuticals, Inc. has 1,135,358 shares outstanding.

Q: What happened to Ampio Pharmaceuticals, Inc.’s price movement after its last earnings report?

Ampio Pharmaceuticals, Inc. reported an EPS of -$0.264 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Compare

510 Followers

AMPE Stock Chart & Stats

Day’s Range― - ―

52-Week Range<$0.01 - $0.48

Previous CloseN/A

Volume38.00

Average Volume (3M)796.00

Market Cap

$2.38K

Enterprise ValueN/A

Total Cash (Recent Filing)$4.09M

Total Debt (Recent Filing)$274.00K

Price to Earnings (P/E)―

Beta-20.63

Next EarningsN/A

EPS EstimateN/A

Last Dividend Ex-Date

Jan 05, 2016

Dividend YieldN/A

Share Statistics

EPS (TTM)-11.09

Shares Outstanding1,135,358

10 Day Avg. Volume57

30 Day Avg. Volume796

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

---

Ampio Pharmaceuticals News

PremiumThe Fly

Biotech Alert: Searches spiking for these stocks today

1y ago

AMPE

BLRX

PremiumThe Fly

Ampio announces NYSE delisting, SEC deregistration

1y ago

AMPE

PremiumCompany Announcements

Ampio Pharmaceuticals Ends Equity Distribution and Alters Strategy

1y ago

AMPE

PremiumCompany Announcements

Ampio Pharmaceuticals Announces Nonclinical Study Success

1y ago

AMPE

PremiumThe Fly

Ampio reports results from OA-201 studies do not support IND submission

1y ago

AMPE

PremiumMarket News

Ampio Pharmaceuticals Announces At-The-Market Stock Offering

1y ago

AMPE

PremiumThe Fly

Biotech Alert: Searches spiking for these stocks today

1y ago

MRK

AMPE

PremiumThe Fly

Ampio announces 20-to-1 reverse stock split

2y ago

AMPE

See All AMPE News

---

Financials

Quarterly

Income Statement >

Ownership Overview

―

Insiders

― Mutual Funds

<0.01% Other Institutional Investors

100.00% Public Companies and

Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Detailed Risk Analysis >

AMPE FAQ

What was Ampio Pharmaceuticals, Inc.’s price range in the past 12 months?

Ampio Pharmaceuticals, Inc. lowest stock price was <$0.01 and its highest was $0.47 in the past 12 months.

What is Ampio Pharmaceuticals, Inc.’s market cap?

Ampio Pharmaceuticals, Inc.’s market cap is $2.38K.

When is Ampio Pharmaceuticals, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Ampio Pharmaceuticals, Inc.’s earnings last quarter?

Ampio Pharmaceuticals, Inc. released its earnings results on May 11, 2023. The company reported -$0.264 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.264.

Is Ampio Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts Ampio Pharmaceuticals, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ampio Pharmaceuticals, Inc. pay dividends?

Ampio Pharmaceuticals, Inc. pays a Notavailable dividend of $209.7 which represents an annual dividend yield of N/A. See more information on Ampio Pharmaceuticals, Inc. dividends here

What is Ampio Pharmaceuticals, Inc.’s EPS estimate?

Ampio Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ampio Pharmaceuticals, Inc. have?

Ampio Pharmaceuticals, Inc. has 1,135,358 shares outstanding.

What happened to Ampio Pharmaceuticals, Inc.’s price movement after its last earnings report?

Ampio Pharmaceuticals, Inc. reported an EPS of -$0.264 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Ampio Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in AMPE

---

Company Description

Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

---

AMPE Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2014","6":"Mar<br/>2014","9":"Nov<br/>2020","12":"Aug<br/>2022","25":"Aug<br/>2023"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.5,42.92307692307692,39.34615384615385,35.76923076923077,32.19230769230769,28.615384615384613,25.038461538461537,21.46153846153846,17.884615384615383,14.307692307692307,10.730769230769226,7.153846153846153,3.576923076923073,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":139.5,"date":1380585600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":139.5,"date":1383264000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":139.5,"date":1385856000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":139.5,"date":1388534400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":139.5,"date":1388534400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.5,"date":1391212800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.5,"date":1393632000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.5,"date":1406851200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.5,"date":1575158400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.56,"date":1604188800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.5,"date":1646092800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.07,"date":1648771200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.5,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >